ACRS Stock Analysis: Aclaris Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 851m USD | 12M Return: 259.8% | US00461U1051 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 9.63M
Qual. Beats: 0
Rev. Trend: -86.2%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Aclaris Therapeutics (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company headquartered in Wayne, Pennsylvania, focused on discovering and developing novel small-molecule and biologic product candidates for immuno-inflammatory diseases. The company was incorporated in 2012 and went public in 2015. As a clinical-stage issuer with no commercial products, Aclaris is pre-revenue and funds its operations through equity financing and capital markets rather than product sales, which is typical for the biopharmaceutical sub-industry.
Its pipeline is centered on modulating immune pathways implicated in atopic, respiratory, and autoimmune conditions. Lead candidate Bosakitug (ATI-045) is an anti-TSLP monoclonal antibody in Phase 2 development across atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and COPD. ATI-2138, a dual ITK/JAK3 inhibitor, is in Phase 2a for T cell-mediated autoimmune diseases, while ATI-052, an anti-TSLP/anti-IL4R bispecific antibody, is in Phase 1b. Earlier-stage assets include ATI-9494 (an oral covalent ITK/TXK inhibitor) and Lepzacitinib (a soft JAK1/3 inhibitor) for dermatologic conditions.
- Bosakitug Phase 2 atopic dermatitis data readout nears
- Cash burn fuels potential dilutive financing risk
- Dupixent competition pressures atopic dermatitis market entry
| Net Income: -69.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.26 > 0.02 and ΔFCF/TA -1.57 > 1.0 |
| NWC/Revenue: 990.3% < 20% (prev 490.9%; Δ 499.4% < -1%) |
| CFO/TA -0.26 > 3% & CFO -52.2m > Net Income -69.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.03 > 1.5 & < 3 |
| Outstanding Shares: last quarter (128.8m) vs 12m ago 5.25% < -2% |
| Gross Margin: 76.34% > 18% (prev 20.55%; Δ 55.78% > 0.5%) |
| Asset Turnover: 4.22% > 50% (prev 8.97%; Δ -4.76% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.42 (Total Current Assets 110.2m - Total Current Liabilities 27.4m) / Total Assets 198.7m |
| B: -4.97 (Retained Earnings -987.6m / Total Assets 198.7m) |
| C: -0.36 (EBIT TTM -71.1m / Avg Total Assets 198.4m) |
| D: 2.61 (Book Value of Equity 143.6m / Total Liabilities 55.1m) |
| Altman-Z'' = -13.14 = D |
| DSRI: 3.0 (Receivables 4.81m/250k, Revenue 8.37m/17.8m) |
| GMI: 0.27 (GM 20.55% / 76.34%) |
| AQI: 0.97 (AQ_t 0.43 / AQ_t-1 0.45) |
| SGI: 0.47 (Revenue 8.37m / 17.8m) |
| TATA: -0.09 (NI -69.7m - CFO -52.2m) / TA 198.7m) |
| Beneish M = -2.45 (Cap -4..+1) = BBB |
As of August 11, 2026, the stock is trading at USD 5.90 with a total of 1,593,720 shares traded. Over the past week, the price has changed by +6.69%, over one month by +5.73%, over three months by +19.19% and over the past year by +259.76%.
Current recommended Stop Loss: 5.40 (which is 8.5% or 1.3 ATR below the current price).
Aclaris Therapeutics has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy ACRS.
- StrongBuy: 3
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 10.2 | 72.9% |
P/S = 101.6555
P/B = 5.0557
P/EG = -0.13
Revenue TTM = 8.37m USD
EBIT TTM = -71.1m USD
EBITDA TTM = -70.6m USD
Long Term Debt = 1.42m USD (estimated: total debt 1.99m - short term 569k)
Short Term Debt = 569k USD (from shortTermDebt, last quarter)
Debt = 2.41m USD (from shortLongTermDebtTotal, last quarter) + Leases 426k
Net Debt = -103.0m USD (calculated: Debt 2.41m - CCE 105.4m)
Enterprise Value = 747.5m USD (850.6m + Debt 2.41m - CCE 105.4m)
Interest Coverage Ratio = unknown (Ebit TTM -71.1m / Interest Expense TTM 0.0)
EV/FCF = -14.30x (Enterprise Value 747.5m / FCF TTM -52.3m)
FCF Yield = -6.99% (FCF TTM -52.3m / Enterprise Value 747.5m)
FCF Margin = -624.8% (FCF TTM -52.3m / Revenue TTM 8.37m)
Net Margin = -832.6% (Net Income TTM -69.7m / Revenue TTM 8.37m)
Gross Margin = 76.34% ((Revenue TTM 8.37m - Cost of Revenue TTM 1.98m) / Revenue TTM)
Gross Margin QoQ = 80.21% (prev none%)
Tobins Q-Ratio = 3.76 (Enterprise Value 747.5m / Total Assets 198.7m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 2.41m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -56.2m (EBIT -71.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.03 (Total Current Assets 110.2m / Total Current Liabilities 27.4m)
Debt / Equity = 0.02 (Debt 2.41m / totalStockholderEquity, last quarter 143.6m)
Debt / EBITDA = 1.46 (negative EBITDA) (Net Debt -103.0m / EBITDA -70.6m)
Debt / FCF = 1.97 (negative FCF - burning cash) (Net Debt -103.0m / FCF TTM -52.3m)
Total Stockholder Equity = 124.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -35.11% (Net Income -69.7m / Total Assets 198.7m)
RoE = -55.89% (Net Income TTM -69.7m / Total Stockholder Equity 124.6m)
RoCE = -56.43% (EBIT -71.1m / Capital Employed (Equity 124.6m + L.T.Debt 1.42m))
RoIC = -32.77% (negative operating profit) (NOPAT -56.2m / Invested Capital 171.5m)
WACC = 11.30% (E(850.6m)/V(853.0m) * Re(11.33%) + D(2.41m)/V(853.0m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 11.33% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 92.15 | Cagr: 30.42%
[DCF] Fair Price = unknown (Cash Flow -52.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.04 | # QB: 0
Revenue Correlation: -86.16 | Revenue CAGR: -37.45% | SUE: 0.38 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.17 | Chg30d=+1.45% | Revisions=-17% | Analysts=8
EPS current Year (2026-12-31): EPS=-0.65 | Chg30d=+0.95% | Revisions=+0% | GrowthEPS=-22.4% | GrowthRev=-25.2%
EPS next Year (2027-12-31): EPS=-0.82 | Chg30d=+0.54% | Revisions=+29% | GrowthEPS=-27.1% | GrowthRev=-8.4%
[Analyst] Revisions Ratio: +7% (up=6, down=5)